Portal de Periódicos da CAPES

Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m‐TOR inhibitors monotherapy?

2011; Wiley; Volume: 105; Issue: 1 Linguagem: Inglês

10.1002/jso.22039

1096-9098

Fabrizio Di Benedetto, Massimiliano Berretta, Nicola De Ruvo, Giuseppe Tarantino, Giuseppe D’Amico, Roberto Ballarin, Rosa Maria Iemmolo, Giorgio Enrico Gerunda,

Liver physiology and pathology

Journal of Surgical OncologyVolume 105, Issue 1 p. 111-112 Letter to the Editor Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy? Fabrizio Di Benedetto PhD, MD, Corresponding Author Fabrizio Di Benedetto PhD, MD [email protected] Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalyLiver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Via del Pozzo, 71-41100 Modena, Italy. Fax: +39.059.4223765.===Search for more papers by this authorMassimiliano Berretta MD, Massimiliano Berretta MD Division of Medical Oncology A, National Cancer Institute, CRO-IRCCS, Aviano, ItalySearch for more papers by this authorNicola De Ruvo MD, Nicola De Ruvo MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorGiuseppe Tarantino MD, Giuseppe Tarantino MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorGiuseppe D'Amico MD, Giuseppe D'Amico MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorRoberto Ballarin MD, Roberto Ballarin MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorRosa Maria Iemmolo MD, Rosa Maria Iemmolo MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorGiorgio E. Gerunda MD, Giorgio E. Gerunda MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this author Fabrizio Di Benedetto PhD, MD, Corresponding Author Fabrizio Di Benedetto PhD, MD [email protected] Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalyLiver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Via del Pozzo, 71-41100 Modena, Italy. Fax: +39.059.4223765.===Search for more papers by this authorMassimiliano Berretta MD, Massimiliano Berretta MD Division of Medical Oncology A, National Cancer Institute, CRO-IRCCS, Aviano, ItalySearch for more papers by this authorNicola De Ruvo MD, Nicola De Ruvo MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorGiuseppe Tarantino MD, Giuseppe Tarantino MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorGiuseppe D'Amico MD, Giuseppe D'Amico MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorRoberto Ballarin MD, Roberto Ballarin MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorRosa Maria Iemmolo MD, Rosa Maria Iemmolo MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorGiorgio E. Gerunda MD, Giorgio E. Gerunda MD Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this author First published: 25 July 2011 https://doi.org/10.1002/jso.22039Citations: 9Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576. 2 Roberts LR, Gores GJ: Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liver Dis 2005; 25: 212–225. 3 Wilhelm SM, Carter C, Tang L, et al.: BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–7109. 4 Llovet J, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390. 5 Guba M, von Breitenbuch P, Steinbauer M, et al.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128–135. 6 Folkman J, Merler E, Abernathy C, et al.: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275–288. (Semin Oncol 2002, 29(6 Suppl 16):15–18). 7 Folkman J., Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15–18. 8 Schumacher G, Oidtmann M, Rosewicz S, et al.: Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34: 1392–1393. Citing Literature Volume105, Issue11 January 2012Pages 111-112 ReferencesRelatedInformation